Insider account of Roivant's SPAC deal — and that $7.3B valuation — reveals a few secrets as Matt Gline positions the company as the new ‘Big Pharma’
It was Oct. 7, 2020, and Matt Gline wasn’t wasting any time.
The CEO of Roivant had word that KKR vet Jim Momtazee’s SPAC had priced late the night before, triggering a green light for anyone interested in pursuing a big check for future operations and riding the financial instrument to Nasdaq. So he wrote a quick email congratulating Momtazee, whom he knew, for the launch.
Oh, and maybe Momtazee would like to schedule something with Gline and his executive chairman, Roivant founder Vivek Ramaswamy, to chat about Roivant and its business?
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.